The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy

Table 1 CEA of peginterferon beta-1a vs IFN beta-1a in Italy from the NHS perspective

Outcomes		peginterferon beta-1a 125 μg	IFN beta-1a 30 μg	IFN beta-1a 22 μg	IFN beta-1a 44 μg
Clinical outs.	LYs	19.94	19.71	19.73	19.81
	QALYs	9.07	8.09	8.19	8.55
[a]			0.98	0.87	0.51
Cost outs. (€)	Drugs & mon.	113,095	92,599	93,511	129,261
	Relapses	8789	9331	9078	8768
	Adverse events	102	153	107	150
	Disease manag.	111,107	120,152	119,651	116,368
	Total cost	233,091	222,235	222,077	254,547
[b]			10,856	11,014	−21,456
ICER (€) [c]			11,112	12,532	Dominant

ISSN: 2056-6115